Genmab A/S (NASDAQ:GMAB) receives an average “Hold” rating from brokerage firms

Genmab A/S (NASDAQ:GMAB) receives an average “Hold” rating from brokerage firms

Shares of Genmab A/S (NASDAQ:GMABget rating) have received an average rating of “Retain” from the thirteen rating firms that currently cover the company, Marketbeat Ratings reports. One investment analyst rated the stock with a sell recommendation, eight issued a hold recommendation and two assigned a buy recommendation to the company. The average 1-year target price among analysts who have updated their coverage on the stock in the past year is $547.62.

Several research companies have recently published reports on GMAB. SVB Leerink raised the price target for Genmab A/S shares from $30.00 to $31.00 and gave the company a “market return” rating in a research report on Thursday, August 11. HC Wainwright raised its price target on Genmab A/S shares from $49.00 to $51.00 and gave the stock a “buy” rating in a research note on Monday, August 22. Morgan Stanley raised its price target on Genmab A/S shares from $29.00 to $31.00 and gave the stock an “underweight” rating in a research note on Monday, August 15. DNB Markets downgraded shares of Genmab A/S from a “buy” rating to a “hold” rating in a research report on Monday, Oct. 17. Finally, TheStreet upgraded shares of Genmab A/S from a “c+” rating to a “b” rating in a research report on Wednesday, August 31.

Institutional Negotiation of Genmab A/S

Several large investors have recently bought and sold shares in the company. International Biotechnology Trust PLC acquired a new shareholding in Genmab A/S in the second quarter for $57,000. Private Capital Group LLC increased its shareholding in Genmab A/S by 14.1% in the second quarter . Private Capital Group LLC now owns 2,677 shares of the company worth $87,000 after acquiring an additional 331 shares during the period. Captrust Financial Advisors increased its shareholding in Genmab A/S by 62.0% in the first quarter. Captrust Financial Advisors now owns 2,658 shares of the company worth $96,000 after purchasing an additional 1,017 shares during the period. Wipfli Financial Advisors LLC acquired a new shareholding in Genmab A/S in the third quarter for $171,000. Ultimately, SG Americas Securities LLC increased its shareholding in Genmab A/S by 4.7% in the third trimester. SG Americas Securities LLC now owns 6,335 shares of the company worth $204,000 after purchasing an additional 285 shares during the period. Institutional investors and hedge funds own 5.51% of the company’s shares.

Genmab A/S share performance

Actions of NASDAQ:GMAB opened at $39.95 on Friday. The company has a market capitalization of $26.3 billion, a PE ratio of 44.39, a price/earnings growth ratio of 1.45, and a beta of 0.94. The company’s 50-day simple moving average is $35.97 and its 200-day simple moving average is $34.02. Genmab A/S has a one year minimum of $26.19 and a one year maximum of $47.07.

Genmab A/S (NASDAQ:GMABget rating) last issued its quarterly earnings data on Wednesday, August 10. The company reported earnings per share (EPS) of $0.41 for the quarter, beating the consensus estimate of $0.21 by $0.20. The company had revenue of $452.86 million in the quarter, compared to analyst estimates of $435.40 million. Genmab A/S had a net margin of 38.42% and a return on equity of 17.12%. Equity research analysts predict that Genmab A/S will post 1.01 EPS for the current fiscal year.

About Genmab A/S

(get rating)

Genmab A/S develops antibody therapies for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

read more

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

This instant news alert was powered by MarketBeat’s financial data and narrative science technology to provide readers with the fastest and most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Genmab A/S, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five actions that major analysts quietly whisper to their clients to buy now before the broader market realizes it… and Genmab A/S was not on the list.

While Genmab A/S currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Leave a Comment